HGH Fragment 176-191
250–500 mcg · Daily
Evidence
- Human Studies
- 3
- Animal Studies
- 20
- Clinical Status
- Research
- Confidence
- Low
- Long-Term Safety
- Unknown — human evidence for the fat-loss claim specifically is thin, and long-term safety data is essentially absent
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
HGH Fragment 176-191 is a synthetic fragment of the C-terminal region of growth hormone that, in animal studies, retains GH's fat-metabolizing effect without significantly affecting blood sugar, IGF-1, or tissue growth the way full-length GH does. Human data supporting this fat-loss-specific effect is far thinner than the animal literature.
Common Protocols
- 250–500 mcg subcutaneous daily, often on an empty stomach
- Sometimes injected near targeted fat deposits based on unproven "spot reduction" theory
Side Effects
- Injection site irritation
- Limited systematic human safety data
Interactions
- No formal interaction data exists
Practical Details
- Cost
- $$
- Typical Vial Size
- 5 mg
- Storage
- Refrigerate after reconstitution
Research Links
Fat-loss-targeted fragment of growth hormone; does not raise GH itself